FIELD: medicine; pharmaceutics.
SUBSTANCE: pharmaceutical formulations contains as reactants 1) betamethasone dipropionate or 2) betamethasone dipropionate combined with gentamicin sulphate or 3) betamethasone dipropionate combined with gentamicin sulphate and clotrimazole. Pharmaceutical formulations contain ointment hydrophobic base containing white petrolatum and target additives - preserving agent and hydrophobic nonaqueous solvent. New pharmaceutical formulations have high antibacterial preserving action, high microbiological purity value and potentised antibacterial specific action showed by produced therapeutic effect and simultaneous prevention of by-effect local complication caused by activation of bacterial and mycotic infections.
EFFECT: prevention of by-effect local complication caused by activation of bacterial and mycotic infections.
18 cl, 11 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
STABILISED PHARMACEUTICAL COMPOSITION OF ANTIMICROBIAL AND ANTIFUNGAL ACTIONS FOR TREATING SKIN DISEASES | 2011 |
|
RU2450808C1 |
PHARMACEUTICAL COMPOSITION POSSESSING ANTI-ALLERGIC AND ANTI-INFLAMMATORY EFFECT | 2004 |
|
RU2281102C2 |
COMBINED PREPARATION FOR TREATING SKIN DISEASES | 2002 |
|
RU2223097C1 |
ANTI-INFLAMMATORY AND ANTI-ALLERGIC COMPOSITION | 2002 |
|
RU2223765C1 |
PHARMACEUTICAL COMPOSITION ELICITING ANTI-INFLAMMATORY AND ANTI-ALLERGIC EFFECT | 2002 |
|
RU2225208C1 |
STABLE PHARMACEUTICAL COMPOSITION LAMIVUDINE | 2015 |
|
RU2587782C1 |
COMBINED PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION | 2018 |
|
RU2736940C2 |
STABLE SOFT DOSAGE FORM OF DIOXIDINE | 2020 |
|
RU2741787C1 |
PHARMACEUTICAL COMPOSITION FOR ALLERGIC AND INFLAMMATORY SKIN DISEASES | 2009 |
|
RU2440108C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING SKIN DISEASES AND METHOD FOR PREPARING IT | 2011 |
|
RU2489144C2 |
Authors
Dates
2008-06-10—Published
2006-09-06—Filed